Table 4.

Time to Neutrophil Recovery, Neutropenia-Related Infectious Complications, and Transfusion Support, According to Treatment Group

Variable GM-CSF Group (N = 110) Placebo Group (N = 122) P Value
Median time to neutrophil recovery with a neutrophil count >500/μL (days)  24  29  .00013-151 
Median duration of febrile episodes >38.5°C (days)  8  10  .50* 
No. of patients with documented infection(s) (%)  74 (67) 88 (72)  .423-152 
No. of infectious events (%) 
 Septicemia  24 (22)  34 (28)  .983-152 
 Pulmonary infection  27 (25)  34 (28) 
 Other documented infection  31 (28) 40 (33)  
 Serious fungal infection  11 (10) 13 (11)  
Median duration of intravenous antibiotic treatment (days)  23  25  .018* 
Median duration of antifungal treatment (days)  11  12  .90* 
Median no. of platelet transfusions per patient  5  5  .67* 
Median no. of red blood cell transfusions per patient  9  11  .10* 
Median duration of hospitalization (days)  30  33 .10* 
Variable GM-CSF Group (N = 110) Placebo Group (N = 122) P Value
Median time to neutrophil recovery with a neutrophil count >500/μL (days)  24  29  .00013-151 
Median duration of febrile episodes >38.5°C (days)  8  10  .50* 
No. of patients with documented infection(s) (%)  74 (67) 88 (72)  .423-152 
No. of infectious events (%) 
 Septicemia  24 (22)  34 (28)  .983-152 
 Pulmonary infection  27 (25)  34 (28) 
 Other documented infection  31 (28) 40 (33)  
 Serious fungal infection  11 (10) 13 (11)  
Median duration of intravenous antibiotic treatment (days)  23  25  .018* 
Median duration of antifungal treatment (days)  11  12  .90* 
Median no. of platelet transfusions per patient  5  5  .67* 
Median no. of red blood cell transfusions per patient  9  11  .10* 
Median duration of hospitalization (days)  30  33 .10* 

*Student's t test.

F3-151

Log-rank test.

F3-152

Chi-square test.

or Create an Account

Close Modal
Close Modal